Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 123   

Articles published

JNJ 101.96 -0.15 (-0.15%)
price chart
Dispute Between Johnson & Johnson and Boston Scientific Moving to Trial
Before the deal closed, however, Guidant faced product recalls, and Johnson & Johnson renegotiated the terms of the deal, ultimately agreeing to pay $21.5 billion.
Longtime BSX-J&J feud heading to trial  Boston Globe
Related articles »  
IBM board adds Johnson & Johnson CEO, former Royal Dutch Shell CEO
Closing out a month that included a landmark deal with Apple, IBM is boosting its board of directors with two new additions who are seasoned chief executives.
IBM Elects Two New Members to Its Board of Directors  MarketWatch
IBM (IBM) Adds Two New Directors (JNJ) (RDS-A)  StreetInsider.com (subscription)
Related articles »  
Johnson & Johnson's Results Boosted by Hepatitis C Drug
Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9.1%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market.
Johnson & Johnson Profit Jumps 13% As Hepatitis Drugs Shine  Forbes
Johnson & Johnson Earnings Good News For Gilead Sciences  Barron's (blog)
Related articles »  
Johnson & Johnson Board Approves Additional $5 Billion Stock Buyback
Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market last week.
Why Johnson & Johnson (JNJ) Stock Is Up Today  TheStreet.com
Johnson & Johnson Announces $5 Billion Share Repurchase Program  MarketWatch
Related articles »  
IBM Adds Johnson & Johnson CEO, Retired Shell Chief to Board
Gorsky, 54, oversaw surgical products and medical devices in different roles at Johnson & Johnson before being named CEO in 2012.
Pharmacyclics/Johnson amp; Johnson Drug Backed for EU Approval
The EU approval of Pharmacyclics (PCYC - Analyst Report) and partner Johnson & Johnson's (JNJ - Analyst Report) oncology drug Imbruvica (ibrutinib) appears well on track with the European Medicines Agency's (EMA) Committee for Medicinal Products for ...
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval  Yahoo News
Related articles »  
Johnson & Johnson Earnings Should Show Pharma Business To Remain Strong
Johnson & Johnson will report its Q2 2014 earnings on July 15. We expect no significant change in the intensity of the main trends driving the company's business.
Johnson & Johnson expecting strong Q2 EPS  IG
Related articles »  
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Johnson & Johnson (NYSE: JNJ ) held a conference call last week to go over the results of its second-quarter financials and give investors a taste of what's to come.
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
Johnson & Johnson CEO: No Plans to Leave US
Johnson & Johnson's strong second-quarter earnings are thanks to the company's focus on long-term goals, particularly in the pharmaceutical business, said CEO Alex Gorsky.
Johnson & Johnson CEO: Not Relocating Overseas  ValueWalk
Related articles »